Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Nuvo Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by JDEVRon Oct 26, 2011 5:48pm
306 Views
Post# 19184331

RE: RE: NRI Viewpoint

RE: RE: NRI Viewpoint
They need to take the RS off the table. That's what is really holding this down.
They will not get institutional investors. That's a pipe dream. Mgmt is out to lunch.
Except for Tom Jones. lol .. He seems smart. The company needs to grow from Pennsaid sales and
hopefully some royalties from PVS (thanks in advance Malincrock). Enough already...  
PS - Gunther needs to stop twiddling his thumbs with WF10 and make some kind of recommendation for next steps.
How can you have any forecast\outlook to go by with NRI? - You just can't.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities